Sign in or create an account to add this stock to your watchlist.
About Kala Pharmaceuticals (NASDAQ:KALA)
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252
Debt
Debt-to-Equity Ratio0.25
Current Ratio20.40
Quick Ratio20.40
Price-To-Earnings
Trailing P/E Ratio-2.60
Forward P/E Ratio-7.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales9,295.96
Cash FlowN/A
Price / CashN/A
Book Value$3.27 per share
Price / Book4.63
Profitability
EPS (Most Recent Fiscal Year)($5.84)
Net Income$-42,210,000.00
Net MarginsN/A
Return on Equity-108.42%
Return on Assets-46.86%
Miscellaneous
Employees37
Outstanding Shares24,560,000
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals (NASDAQ:KALA) released its earnings results on Thursday, May, 10th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.00. View Kala Pharmaceuticals' Earnings History.
What price target have analysts set for KALA?
5 brokerages have issued 1 year price targets for Kala Pharmaceuticals' shares. Their predictions range from $19.00 to $46.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $35.80 in the next year. View Analyst Ratings for Kala Pharmaceuticals.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include Innoviva (INVA), Zogenix (ZGNX), PTC Therapeutics (PTCT), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Impax Laboratories (IPXL), Endo International (ENDP), TherapeuticsMD (TXMD), Immuron (IMRN), Mallinckrodt (MNK), Radius Health (RDUS), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Biohaven Pharmaceutical (BHVN) and WAVE Life Sciences (WVE).
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Exec. Chairman, Pres & CEO (Age 52)
- Dr. Hongming Chen Sc.D., Chief Scientific Officer (Age 47)
- Dr. Kim Brazzell Ph.D., Chief Medical Officer (Age 65)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CFO, Corp. Controller & Treasurer (Age 43)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Has Kala Pharmaceuticals been receiving favorable news coverage?
News headlines about KALA stock have been trending positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a news impact score of 0.40 on Accern's scale. They also assigned news articles about the company an impact score of 47.09 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Kala Pharmaceuticals' major shareholders?
Kala Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.10%), Millennium Management LLC (4.06%), Wells Fargo & Company MN (1.48%), JPMorgan Chase & Co. (0.82%), Asymmetry Capital Management L.P. (0.55%) and Northern Trust Corp (0.54%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.
Which major investors are selling Kala Pharmaceuticals stock?
Which major investors are buying Kala Pharmaceuticals stock?
KALA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Asymmetry Capital Management L.P., Wells Fargo & Company MN, Northern Trust Corp, Sofinnova Ventures Inc, Schwab Charles Investment Management Inc. and Tiverton Asset Management LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $15.14.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $378.26 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kala Pharmaceuticals (NASDAQ:KALA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Their average twelve-month price target is $35.80, suggesting that the stock has a possible upside of 136.46%. The high price target for KALA is $46.00 and the low price target for KALA is $19.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $35.80 | $35.80 | $35.80 | $36.80 |
| Price Target Upside: | 136.46% upside | 139.95% upside | 139.95% upside | 96.79% upside |
Kala Pharmaceuticals (NASDAQ:KALA) Consensus Price Target History
Kala Pharmaceuticals (NASDAQ:KALA) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Kala Pharmaceuticals (NASDAQ:KALA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kala Pharmaceuticals (NASDAQ KALA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.58%
Institutional Ownership Percentage: 76.83%
Kala Pharmaceuticals (NASDAQ KALA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/8/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 25,000 | $12.93 | $323,250.00 | |  |
| 2/1/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 362,240 | $15.00 | $5,433,600.00 | | |
| 1/29/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 72,760 | $14.97 | $1,089,217.20 | | |
| 1/26/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 22,760 | $14.93 | $339,806.80 | | |
| 1/24/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 64,637 | $14.91 | $963,737.67 | | |
| 1/22/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 75,000 | $14.98 | $1,123,500.00 | | |
| 1/19/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 74,931 | $14.95 | $1,120,218.45 | | |
| 1/12/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 240,484 | $13.28 | $3,193,627.52 | | |
| 1/10/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 170,338 | $12.83 | $2,185,436.54 | | |
| 7/25/2017 | Longitude Capital Partners Ii, | Major Shareholder | Buy | 215,000 | $15.00 | $3,225,000.00 | | |
| 7/25/2017 | Orbimed Advisors Llc | Insider | Buy | 319,333 | $15.00 | $4,789,995.00 | | |
| 7/25/2017 | Rajeev M Shah | Director | Buy | 533,333 | $15.00 | $7,999,995.00 | | |
| 7/20/2017 | Associates L.L.C. Cdk | Major Shareholder | Buy | 215,000 | $15.00 | $3,225,000.00 | | |
(Data available from 1/1/2013 forward)
Kala Pharmaceuticals (NASDAQ KALA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Q2 2018 EPS Estimates for Kala Pharmaceuticals (KALA) Increased by Analyst
www.americanbankingnews.com - May 18 at 7:37 AM |
| Kala Pharmaceuticals Expected to Earn Q1 2019 Earnings of ($0.64) Per Share (KALA)
www.americanbankingnews.com - May 17 at 8:48 AM |
| Wedbush Reaffirms Outperform Rating for Kala Pharmaceuticals (KALA)
www.americanbankingnews.com - May 15 at 4:49 PM |
| Kala Pharmaceuticals (KALA) Posts Earnings Results, Meets Expectations
www.americanbankingnews.com - May 12 at 12:28 AM |
 | Kala Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 10:51 AM |
| Kala Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - May 8 at 10:22 AM |
| Zacks: Brokerages Expect Kala Pharmaceuticals (KALA) to Post -$0.45 Earnings Per Share
www.americanbankingnews.com - May 7 at 11:04 PM |
| Kala Pharmaceuticals (KALA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 1:48 AM |
| Kala Pharmaceuticals (KALA) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 3 at 1:31 PM |
| Kala Pharmaceuticals (KALA) Lowered to Hold at BidaskClub
www.americanbankingnews.com - May 1 at 9:08 AM |
| -$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter
www.americanbankingnews.com - April 20 at 9:18 PM |
| Brokers Set Expectations for Kala Pharmaceuticals' Q1 2018 Earnings (KALA)
www.americanbankingnews.com - April 20 at 7:10 AM |
| Kala Pharmaceuticals (KALA) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - April 10 at 5:03 PM |
| Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 10 at 10:55 AM |
| Kala Pharmaceuticals (KALA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 2:01 AM |
| Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
finance.yahoo.com - April 9 at 10:53 AM |
| Kala Pharmaceuticals (KALA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:22 AM |
| Kala Pharmaceuticals (KALA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| Zacks Investment Research Upgrades Kala Pharmaceuticals (KALA) to Hold
www.americanbankingnews.com - April 4 at 6:26 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 3 at 11:18 PM |
| Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
finance.yahoo.com - April 3 at 10:55 AM |
| Short Interest in Kala Pharmaceuticals Inc (KALA) Drops By 21.7%
www.americanbankingnews.com - March 31 at 2:56 AM |
 | Kala Pharmaceuticals 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 28 at 10:37 AM |
| Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 27 at 10:55 AM |
| Kala Pharmaceuticals (KALA) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - March 27 at 7:25 AM |
 | BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
www.reuters.com - March 26 at 11:10 AM |
| Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 26 at 11:10 AM |
| Kala Pharma reports 4Q loss
finance.yahoo.com - March 26 at 11:10 AM |
| Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
finance.yahoo.com - March 19 at 10:45 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - March 17 at 9:10 PM |
| Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 16 at 1:54 AM |
| BRIEF-Kala Pharma Says Increased Size Of Board From 9 To 10
www.reuters.com - March 5 at 10:59 AM |
| Emory University Acquires New Stake in Kala Pharmaceuticals Inc (KALA)
www.americanbankingnews.com - March 4 at 2:59 PM |
| Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 19 at 1:46 AM |
| Kala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 17 at 2:10 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM |
| Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - February 12 at 3:16 AM |
| Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 11 at 9:42 PM |
| Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)
www.americanbankingnews.com - February 4 at 11:08 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in Stock
www.americanbankingnews.com - January 30 at 6:32 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM |
| Kala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 28 at 2:34 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - January 26 at 5:04 AM |
| Kala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & Co
www.americanbankingnews.com - January 26 at 12:22 AM |
| Kala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:40 AM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 Shares
www.americanbankingnews.com - January 24 at 9:08 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of Stock
www.americanbankingnews.com - January 24 at 9:08 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM |
| Kala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in December
www.americanbankingnews.com - January 14 at 2:32 AM |
Kala Pharmaceuticals (NASDAQ:KALA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kala Pharmaceuticals (NASDAQ:KALA) Income Statement, Balance Sheet and Cash Flow Statement
Kala Pharmaceuticals (NASDAQ KALA) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
